A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related

Exclusion Criteria

• •Subjects with history of another primary cancer within 5 years
• •Central nervous system metastasis and clinically significant central nervous system disease
• •Previous or current coexistence of hepatic encephalopathy
• •Currently present with symptomatic third space fluid accumulation
• •Hypertension that is poorly controlled, as determined by researchers (i.e., arterial hypertension that remains uncontrolled despite standard treatment)
• •Known history of neurological or mental disorder, including epilepsy or dementia
• •Suffering from active autoimmune diseases, or other significant ongoing immune rejection based on pathology and clinical diagnosis
• •Prior exposure to any cell therapy such as, but not limited to killer (NK) cells, cytokine-induced killer (CIK) cells, dendritic cells (DC), cytotoxic T lymphocytes (CTL), stem cell therapy
• •Positive for HCV - RNA test or positive for HAV IgM antibody or positive for HDV IgM antibody; or there is current evidence indicating the presence of HEV infection
• •Allergy to immunotherapy drugs and lymphodepleting chemotherapy (cyclophosphamide and fludarabine)
• •Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation